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Prolonged Course of Toxic Shock Syndrome Associated 
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Enterotoxins G and I 
Richard D. Meyer, MD;* Steven R. Monday, PhD;+ Gregory A. Bohach, PhD;+ 
and Patrick M. Schlievert, PhD* 
Toxic shock syndrome (TSS), which may be hfe-threat- 
ening, is defined by clinical and laboratory evidence of 
fever, rash, hypotension, and multisystem abnormalities 
in the absence of other causes. Most cases are nonmen- 
strual in origin. I-* Whereas Staphylococcus aureus TSS 
toxin-l causes the vast majority of menstrual cases, it 
causes only about half of other cases.” Staphylococcal 
enterotoxins (SEs) were implicated in nonmenstrual TSS 
cases shortly after the role of TSS toxin-l was elucidated, 
and currently, SEs that are reported to be associated with 
TSS are SEs A, B, C, D, G, H, and I, with SE-B most com- 
monly reported and SE-G and SE-I most recently reported, 
albeit the latter two with scant clinical details.2s4-8 The 
following case associated with SE-G and SE-I illustrates 
the consequences of these immunomodulatory pyrogenic 
toxin superantigens over a prolonged course, as well as 
pitfalls in their diagnosis and management. 
CASE REPORT 
A 57-year-old woman was transferred to Northridge Hos- 
pital Medical Center (NHMC) on October 3, 1997, for 
rehabilitation. She had sustained multiple traumata on 
May 2,1997, which led to admission to an intensive care 
unit (ICU) in another hospital. She suffered a C2 odon- 
toid fracture, intracranial bleeding, right hemothorax and 
lung contusion, and multiple fractures. She was initially 
quadriplegic and hypotensive; the serum creatinine was 
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1.7 mg/dL. The patient underwent multiple surgeries, 
received intravenous cefazolin and corticosteroids, devel- 
oped adult respiratory distress syndrome (ARDS), and 
remained dependent on mechanical ventilation. She tem- 
porarily needed hemodialysis. 
On hospital day 38, fever ensued (39.5”C) while the 
patient received intravenous vancomycin therapy for pre- 
sumptive methicillin-resistant S. aweus (MRSA) pneu- 
monia. Blood pressure dropped to 70 mm Hg systolic, 
and oliguria, hypotension, leukocytosis (white blood cell 
count [WBC] 19,40O/mm”) followed. Ceftazidime ther- 
apy was added, but the patient remained febrile (39.7%) 
the WBC rose further, and nonoliguric acute tubular 
necrosis secondary to hypotension and “occult sepsis” 
were diagnosed; an erythematous rash on the patient’s 
back was ascribed to possible allergy to ceftazidime. 
The patient was transferred to the ICU of another 
medical center on June 12,1997, for further management. 
She was febrile on admission while receiving intravenous 
ceftazidime and vancomycin, the latter of which was 
given for approximately 3 months. A consultant initially 
noticed “diffuse erythroderma,” which suggested drug 
allergy, and omitted cefiazidime therapy. Purulent tracheal 
secretions continually yielded MRSA. Other anitmicro- 
bials were administered for finding of gram-negative 
bacilli in cultures from various sites, but infections there 
did not seem to have contributed to recurrent bouts of 
fever, hypotension, and leukocytosis. Color photographs 
documented persistent diffuse erythema. On day 7 empir- 
ical therapy with ceftazidime and amphotericin B was 
started, and fluconazole was also briefly administered to 
reduce fever (39.9”C). Dopamine treatment was needed, 
and leukocytosis (WBC 18,800/mm3) increased. Creati- 
nine rose further, and hemodialysis continued. On day 11 
a covering consultant administered intravenous 
immunoglobulin initially at 1 g/kg and then 0.5 g/kg 
thrice on alternate days after having considered a diag- 
nosis of TSS; this intervention was not documented in 
transfer summaries, consultants’ notes, or in telephonic 
communications in 1997. It led to a somewhat salutary 
response, including return of WBC to normal. Erythema- 
tous rash continued, and on day 37, fever recurred. Van- 
corny& and antibacterials directed against gram-negative 
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bacilli were given for “probable pneumonia,” but fever 
and hypotension continued, requiring intravenous 
phenylephrine on day 47. The WBC rose to 37,900/mm3. 
The patient slowly improved, but on day 80 she sus- 
tained another episode of fever, erythema, and leukocy- 
tosis. Amphotericin B was empirically administered, 
complicated by atria1 fibrillation. On day 104 multiple 
antibacterials, including vancomycin, were given for treat- 
ment of fever. Pressors were required again; leukocytosis 
worsened. On day 130 “sepsis syndrome” was diagnosed, 
but blood cultures remained negative and no cultural 
confirmation was made. Imipenem, ciprofloxacin, and 
vancomycin therapy was given, and transfer to NHMC 
took place October 3,1997. 
On admission to rehabilitation service the patient 
had multiple decubitus ulcers, including on the occiput. 
Imipenem and ciprofloxacin were continued, despite no 
clear source of infection. Sputum culture yielded MRSA. 
Dialyses continued. On day 4, temperature rose to 39.2”C. 
Later ceftazidime and gentamicin were given. Chest com- 
puted tomography (CT) showed pleural effusions, vol- 
ume loss, atelectasis, and perihilar alveolar air space filling 
defect infiltrates. Cultures of tracheal aspirate and occip- 
ital decubitus ulcer yielded MRSA susceptible only to van- 
comycin, rifampin, and tetracycline. White blood cell 
count increased to 13,200/mm3. A consultant’s examina- 
tion on day 5 showed tachypnea, tachycardia, diffuse ery- 
thema of the skin, multiple decubitus ulcers, and no 
exudate at the gastrojejunostomy (G-J) tube site. Van- 
corny& and minocycline were administered, along with 
local mupirocin at the GJ site and chlorhexidine. Leuko- 
cytosis worsened. On day 6, fever recurred, lethargy 
ensued, erythematous rash increased, leukocytosis 
increased further (WBC 16,900/mm3 with 35% immature 
forms); hypotension and tachypnea along with a heart 
rate of 156 beats per minute associated with atria1 flut- 
ter with 2:l block necessitated transfer to the ICU. 
Fluid resuscitation and levarterenol were required to 
correct hypotension (BP 60/40 mm Hg), and the atrial 
flutter was converted. Other findings included obtunda- 
tion, diffuse blanching erythema, and extensive occipital 
decubitus ulcers. Supportive care, including mechanical 
ventilation and vancomycin, continued; meropenem was 
given. Sepsis syndrome with toxic erythema was diag- 
nosed. On day 7, mental status improved, but fever per- 
sisted (temperature 39.4”C) and WBC rose to 
26,400/mm3. By day 10, fevers had somewhat abated, but 
pressors were still required, and the leukocytosis per- 
sisted; indium WBC scan was negative except for slightly 
increased activity at the occiput. Antibacterial therapy 
was continued, as was dialysis. 
On day 15, erythema increased, leukocytosis worsened 
(WBC 38,600/n&) and hypotension recurred; diphenhy- 
dramine and hydrocortisone were administered, and 
minocyclme and meropenem were omitted because of 
possible drug allergy. An “antibiotic holiday” followed, 
accompanied by some clinical improvement, although 
leukocytosis persisted, associated with new eosinophilia. 
Search for other infections, including fungal, was negative. 
On day 31, with the finding of strawberry tongue 
and increased subconjunctival injection in both eyes, a 
tentative diagnosis of persistent, recurrent TSS was made. 
An isolate from tracheal aspirate of MRSA (isolate No. 1) 
was sent to a reference laboratory (MRL Reference Lab 
oratory, Cypress, California) for TSS toxin analysis (later 
results showed that TSS toxin-l and enterotoxin B were 
not produced), serum was sent for antibody detection 
against TSS toxin-l (MRL Reference Laboratory; later 
result indicated antibody present) and for Tcell analysis 
and quantitative serum immunoglobulin levels. Intra- 
venous immunoglobulin, 0.35 g/kg, was given pending 
results. Five additional daily intravenous immunoglobu- 
lin infusions of 0.35 to 0.4 g/kg were given. CD4+ cell 
count was 2220/mm3 (normal, 400-1700) and CDS+ cells, 
1812/mm3 (normal, 240-1220). Serum IgG level was 465 
mg/dL (normal, 613-1245); IgM, 30 mg/dL (normal, 
55-334); and IgA was normal. Fever decreased and the 
patient improved, although leukocytosis persisted. By day 
44, the patient was more alert and being weaned from the 
ventilator. Erythema had decreased, and the WBC had 
decreased from 35,500/mm3 to 19,800/mm3 after the 
third dose of intravenous immunoglobulin. Audiogram 
showed profound sensorineural hearing loss in both ears. 
Cultures from the G-J tube site, trachea, and occiput 
yielded MRSA. Mild subconjunctival injection, intermit- 
tent erythema, and low grade fevers again led to admin- 
istration of a second course of five infusions of 
intravenous immunoglobulin on days 53 to 61. The WBC 
fell to normal and fever abated. Multiple nails were lost. 
Eradication measures against MRSA were again unsuc- 
cessful and led to rifampin resistance in MRSA. 
On day 75, the G-J tube was removed. A long hospi- 
talization followed with need for dialyses and breakdown 
of the former G-J tube site, with culture yielding MRSA. 
Intermittent unexplained leukocytosis occurred. The 
patient returned to the rehabilitation service on day 126. 
Local surgical exploration, in March 1998, of the old 
G-J site showed a retained suture, which was removed. 
Urine output increased and the patient was changed to 
peritoneal dialysis. Tracheal aspirate cultures continued to 
show MRSA. In April 1998, levels of CD4+ and CD8+ cells 
were normal. The patient was discharged in a wheelchair 
on April 28,1998. A nonhealing tracheocutaneous fistula, 
which along with the occipital ulcer was colonized with 
MRSA, was closed. 
Several episodes of unexplained leukocytosis 
occurred, and the patient was briefly re-admitted on 
November 30,1998, for intravenous vancomycin therapy. 
Nonetheless, as dialysis continued, leukocytosis recurred 
(e.g., WBC 21,200/mm3) and intercurrent urinary tract 
infections were treated. Worsening of the occipital decu- 
bitus ulcer led to re-admission February 8, 1999. Methi- 
cillin-resistant S. aureu~ (isolate 2) was present only in the 
occipital wound. Vancomycin was given again, and plastic 
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surgical debridement achieved good response. Serum was 
obtained for antibody determination. No intravenous 
immunoglobulin could be obtained. The patient died else- 
where in 2000 while dependent on dialysis. 
Isolates Nos. 1 and 2 were analyzed by standard meth- 
ods. A multiplex polymerase chain reaction (PCR) assay 
for 10 toxin genes currently known to be associated with 
staphylococcal TSS was performed.9 Results indicated 
that both isolates harbored the structural genes for SE-G 
and SE-I. Genes for TSS toxin-l or other enterotoxins were 
not detected in either isolate. Antibody against SE-G was 
measured by enzyme-linked immunosorbent assay @ISA) 
and found to be elevated at a titer of 1: 1280 compared 
with 1:640 found in intravenous immunoglobulin, indi- 
cating past exposure.1o 
DISCUSSION 
The patient presented here exhibited multiple episodes of 
TSS (Table l), including approximately six at two other 
institutions, before definitive management, which included 
repeated courses of intravenous immunoglobulin infu- 
sions, and subsequent resolution of focal infections con- 
trolled intoxication. The nosology is not entirely clear as 
to whether the episodes were recurrences or variations 
on a continuum of chronic disease; certainly the patient 
showed a scarlet fever-like rash for more than 5 months 
and later had bouts of unexplained leukocytosis. The 
course of the rash was longer than that of previously 
described “late” rashes several weeks after a bout of TSS. ‘sl ’ 
Considerable morbidity included not just prolonged hos- 
pitalizations and attendant, almost assuredly unnecessary, 
use of antibacterial and antifungal agents with their toxi- 
city (e.g., hearing loss and cardiac arrythmias) but also 
years of continued dependency on renal dialysis. The ele- 
vated antibody titer to SE-G found long alter (about 1 year) 
administration of intravenous immunoglobulin reflected 
host response and certainly was not related to the distant 
intravenous immunoglobulin use. The prior antibacterial 
therapy and nosocomial acquisition are consistent with 
prior nonmenstrual cases of toxic shock syndrome, but the 
recurrences are not.11’12 Although not actively sought, no 
other nosocomial cases were noted, perhaps because of 
isolation procedures for MRSA. 
Staphylococcal enterotoxins are moderate molecu- 
lar weight protein toxins that not only produce emesis 
in some settings but, like TSS toxin-l and the pyrogenic 
exotoxins of Streptococcus pyogenes, act as superanti- 
gens. Thus, they bind major histocompatibility complex 
(MHC) class II proteins, stimulate T lymphocytes depen- 
dent on the VB of the T lymphocyte receptor, and cause 
their clonal proliferation; they also cause sustained 
release of cytokines, such as tumor necrosis factor, inter- 
leukins and interferon-y, the last of which can suppress 
immunoglobulin secretion.*a4 Findings in this patient 
Table 1. Case Criteria for Toxic Shock Syndrome* 
Fever with temperature 238.9% 
Rash (e.g., etythroderma) 
Hypotension 
Multisystem disease 
Mucous membrane: conjunctival injection, strawberry tongue, renal 
insufficiency 
Central nervous system: altered level of consciousness 
Desquamation (loss of nails) 
Absence of other possible causes 
*See text for compatible immunologic abnormalities. 
included compatible clinical features, and laboratory fea- 
tures of nonspecific clonal T-lymphocyte activation and 
depression of IgG and IgM levels, with possible incom- 
plete inability to form potentially protective antibody.* 
Serum immunoglobulin levels reverted to normal long 
after intravenous immunoglobulin therapy, but antibody 
against SE-G later was found. The patient’s clinical 
course and the experimental finding of increased pro- 
duction of other toxins at 37” to 40°C suggest that the 
wound isolates were more significant than the sputum 
isolates.* Although clonal typing of the isolates from the 
patient was not done, it is likely that they were the 
same. 
The clinical manifestations of the staphylococcal tox- 
ins, including TSS toxin-l, SEs, and others, are protean. 
The interactions between the toxins and a diverse vari- 
ety of hosts, including early neonates (TSS toxin-l), 
patients with acquired immunodeficiency syndrome 
(AIDS) (TSS toxin-l, SE-A, SE-B), human T-cell lym- 
photrophic viral infections, and rarely, in children with 
Kawasaki syndrome-like illness (SE-B),‘“-” lead to far-rang- 
ing clinical findings. In addition, Lina and colleagues 
recently suggested, based upon fmding TST toxin-l and 
SEs in cases of staphylococcal scarlet fever, that it may be 
an abortive form of TSS.‘* 
Staphylococcal enterotoxin-G and SE-I were origi- 
nally isolated from a S. aureus from human nares and 
shown to have both emetic properties and those of a 
superantigen. l9 Jarraud and colleagues recently used PCR 
to detect SE-G and SE-I genes in strains sent to a reference 
laboratory and, subsequently, found these isolates did not 
produce other known SEs, exfoliative toxins, or TSS toxin- 
1.’ They reported that 9 of 170 TSS cases were linked to 
SE-G and SE-I; only one was menstrual in origin, and no 
information on antibiotic susceptibility or nosocomial 
acquisition was given. Linkage to staphylococcal scalded 
skin syndrome was shown.’ The current requirement for 
laboratory confirmation of diagnosis lies in PCR ampliti- 
cation done in a reference laboratory, as in the present 
case and in the French study,’ illustrating the need for ear- 
lier diagnosis and presumptive therapy before laboratory 
confirmation. Moreover, the limited usefulness of the com- 
mercially available toxin analysis, especially in nonmen- 
strual TSS, is shown by the present case. 
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Therapy includes supportive measures, use of appro- 
priate antibacterial therapy (with consideration of clin- 
damycin use if the isolate is susceptible), drainage of focal 
infections, and in parallel with the convincing demon- 
stration of its efficacy in treatment of streptococcal TSS 
and fasciitis,*O infusions of intravenous itnmunoglobulin. 
Although use of a single dose of intravenous immunoglob- 
ulin has been suggested,’ experience in streptococcal 
disease and in this patient suggests the need for multiple 
infusions or titration to clinical response. Commercial 
intravenous immunoglobulin may have nonspecific prop- 
erties, but it has also been shown to contain high con- 
centrations of antibodies to eight different staphylococcal 
superantigens and to inhibit T-cell activation by them.*l 
Assays for SE-G and SE-I were not done in that study or 
in preparations used for this patient, but the clinical 
response argues for their presence. Since the superanti- 
gens are bacterial virulence factors, experimental vaccine 
work with SE-A devoid of that property is one theoretic 
approach to protection.** 
CONCLUSION 
Nonmenstrual TSS may be confused with other condi- 
tions, which in the nosocomial setting are, most itnpor- 
tantly, sepsis itself and drug allergy. It has a higher 
case-fatality rate than does menstrual TSSz3 and is prob- 
ably underdiagnosed. Toxic shock syndrome associated 
with SE-G and SE-I, which is certainly underdiagnosed, is 
probably similar to that caused by other staphylococcal 
toxins, but this case had a prolonged course with promi- 
nent erytbroderma. Reliance on antibacterial agents alone 
is inappropriate, and appropriate acute management of 
TSS includes clinical suspicion, supportive care, adminis- 
tration of intravenous imtnunoglobulin, and careful atten- 
tion to resolution of focal infection. 
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